OMEROS CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.59 USD | +2.28% |
|
-2.14% | +9.83% |
| Apr. 01 | Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024. | CI |
| Apr. 01 | Omeros Corporation announces an Equity Buyback for $50 million worth of its shares. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.5M | Capitalization | 203M |
|---|---|---|---|---|---|
| Net income 2024 * | -138M | Net income 2025 * | -135M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 31.3 x |
| P/E ratio 2024 * |
-1.68
x | P/E ratio 2025 * |
-1.96
x | Employees | 198 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Omeros Corporation
More recommendations
More press releases
| 1 day | -1.40% | ||
| 1 week | -5.90% | ||
| Current month | +11.43% | ||
| 1 month | -6.65% | ||
| 3 months | -10.34% | ||
| 6 months | +180.80% | ||
| Current year | +7.34% |
1 week
3.32
3.74
1 month
2.973.92
Current year
2.615.14
1 year
0.927.80
3 years
0.9218.59
5 years
0.9225.46
10 years
0.9230.23
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 94-06-15 | |
Michael Jacobsen
DFI | Director of Finance/CFO | 65 | 13-07-31 |
Andreas Grauer
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 12-09-26 |
Leroy Hood
BRD | Director/Board Member | 85 | 01-02-28 |
Thomas Cable
BRD | Director/Board Member | 84 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 3.595 | +2.42% | 17 894 |
| 24-05-10 | 3.51 | -1.40% | 198,185 |
| 24-05-09 | 3.56 | +0.85% | 146,675 |
| 24-05-08 | 3.53 | -3.02% | 166,363 |
| 24-05-07 | 3.64 | -0.82% | 148,229 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Companyâs lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.51
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.34% | 203M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- OMER Stock